Kristen Zakian1, Hedvig Hricak2,
Nicole Ishill3, Victor Reuter4, Steven Eberhardt5,
Chaya Moskowitz3, Amita Shukla-Dave, Liang Wang, Peter Scardino6,
James Eastham, Jason Koutcher
1Medical Physics, Memorial
Sloan-Kettering Cancer Center, New York, NY, United States; 2Radiology,
Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 3Epidemiology
and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY,
United States; 4Pathology, Memorial Sloan-Kettering Cancer Center,
New York, NY, United States; 5Radiology, University of New Mexico,
NM, United States; 6Surgery, Memorial Sloan-Kettering Cancer
Center, New York, NY, United States
The
purpose of this study was to determine whether pre-treatment endorectal
MRI/MRSI can predict biochemical relapse (BCR) after radical prostatectomy (RP). 130 of
202 patients who underwent endorectal MRI/MRSI in 2000-2002 followed by RP
satisfied data quality criteria and were followed until Jan. 2009. MRI risk
score was assigned based on local disease extent. An MRSI index lesion comprised of voxels
with elevated [Cho+Cr]/Cit volume was designated. MRI risk score, MRSI index
lesion volume and the presence of high grade MRSI voxels correlated with
time-to-biochemical failure after radical prostatectomy even when adjusted
for clinical stage, biopsy Gleason score and PSA.
Keywords